

VI. Anhang

1. Literaturverzeichnis

- Auclair 1978** Auclair C, de Prost D, Hakim J. *Superoxide anion production by liver microsomes from phenobarbital treated rat*. *Biochem Pharmacol.* 1978, 27 (3):355-8
- Balazy 1991** Balazy M. *Metabolism of 5,6-epoxyeicosatrienoic acid by the human platelet. Formation of novel thromboxane analogs*. *J Biol Chem.* 1991, 15, 266 (35):23561-7
- Bauersachs 1996** Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. *Nitric oxide attenuates the release of endothelium-derived hyperpolarising factor*. *Circulation* 1996, 94 (12):3341-3347
- Bolz 1999** Bolz SS, de Wit C, Pohl U. *Endothelium-derived hyperpolarizing factor but not NO reduces smooth muscle Ca²⁺ during acetylcholine-induced dilation of microvessels*. *Br J Pharmacol.* 1999, 128 (1):124-34
- Bolz 2000** Bolz SS, Fissthaler B, Pieperhoff S, De Witt C, Fleming I, Busse R, Pohl U. *Antisense oligonucleotides against cytochrome P450 2C8 attenuate EDHF-mediated Ca²⁺ changes and dilation in isolated resistance arteries*. *FASEB* 2000, 14:255-260
- Bourcier 1997** Bourcier T, Sukhova G, Libby P. *The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis*. *J Biol Chem.* 1997, 20, 272 (25):15817-24
- Brand 1996** Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. *Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion*. *J Clin Invest.* 1996, 1, 97 (7):1715-22
- Brunner 2006** Brunner F, Brás-Silva C, Cerdeira AS, Leite-Moreira AF. *Cardiovascular endothelins: Essential regulators of cardiovascular homeostasis*. *Pharmacol Ther.* 2006, 2; [Epub ahead of print]
- Busse und Fleming 1995** Busse R, Fleming I. *Regulation and functional consequences of endothelial nitric oxide formation*. *Ann Med.* 1995, 27 (3):331-40

- Campbell 1996** Campbell WB, Gebremedhin d, Pratt P, Harder DR. *Identification of epoxyeicosatrienoic acids as endothelium derived hyperpolarising factors*. Circ Res. 1996, 78 (3):415-423
- Capdevila 1981** Capdevila J, Parkhill L, Chacos N, Okita R, Masters BS, Estabrook RW. *The oxidative metabolism of arachidonic acid by purified cytochromes P-450*. Biochem Biophys Res Commun. 1981, 31, 101 (4):1357-63
- Collen 1980** Collen D. *On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture*. Thromb Haemost. 1980, 18, 43 (2):77-89
- Collins 1995** Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. *Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers*. FASEB J. 1995, 9 (10):899-909
- Crespi und Miller 1997** Crespi CL, Miller VP. *The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase*. Pharmacogenetics. 1997, 7 (3):203-10
- Dai 2001** Dai D, Zeldin D, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. *Polymorphisms in human CYP 2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid*. Pharmacogenetics 2001, 11:597-607
- Daikh 1994** Daikh BE, Lasker JM, Raucy JL, Koop DR. *Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9*. J Pharmacol Exp Ther. 1994, 271 (3):1427-33
- Davies 1993** Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. *The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis*. J Pathol. 1993, 171 (3):223-9
- Dickmann 2001** Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. *Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans*. Mol Pharmacol. 2001, 60 (2):382-7
- Dreisbach 2005** Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, Rettie AE, Kim H, Farin FM, Hamm LL, Lertora JJ. *The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension*. Am J Hypertens. 2005, 18

(10):1276-81

- Edwards 1998** Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. *K⁺ is an endothelium-derived hyperpolarizing factor in rat arteries*. *Nature* 1998, 19, 396 (6708):269-72
- Esper 2006** Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. *Endothelial dysfunction: a comprehensive appraisal*. *Cardiovasc Diabetol*. 2006, 23, 5:4
- Fang 1997** Fang X, Kaduce TL, Weintraub NL, Spector AA. *Cytochrome P450 metabolites of arachidonic acid: rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells*. *Prostaglandins Leukot Essent Fatty Acids*. 1997, 57 (4-5):367-71
- Fang 2001** Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD, Spector AA. *Pathways of Epoxyeicosatrienoic Acid Metabolism in Endothelial Cells*. *J Biol Chem* 2001, 276:14866-14874
- Fichtlscherer 2004** Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. *Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease*. *Circulation*. 2004, 20, 109 (2):178-83
- Fisslthaler 1999** Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. *Cytochrome P450 2C is an EDHF synthase in coronary arteries*. *Nature*. 1999, 30, 401 (6752):493-7
- Fisslthaler 2003** Fisslthaler B, Michaelis UR, Randriamboavonjy V, Busse R, Fleming I. *Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression*. *Biochim Biophys Acta*. 2003, 17, 1619 (3):332-9
- Fleming 2000** Fleming I. *Cytochrome P450 2C is an EDHF synthase in coronary arteries*. *Trends Cardiovasc Med*. 2000, 10 (4):166-70
- Fleming 2001/a** Fleming I. *Cytochrome P450 and vascular homeostasis*. *Circ Res*. 2001, 26, 89 (9):753-62
- Fleming 2001/b** Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R. *Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries*. *Circ Res*. 2001, 19, 88 (1):44-51

- Fleming 2004** Fleming I. *Cytochrom P450 epoxygenases as EDHF synthase(s)*. Pharmacol Res. 2004, 49:525-533
- Fleming und Busse 1999** Fleming I, Busse R. *NO: the primary EDRF*. J Mol Cell Cardiol. 1999, 31 (1):5-14
- Fleming und Busse 2006** Fleming I, Busse R. *Endothelium-derived epoxyeicosatrienoic acids and vascular function*. Hypertension. 2006, 47 (4):629-33
- Gerhard 1996** Gerhard M, Roddy MA, Creager SJ, Creager MA. *Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans*. Hypertension. 1996, 27 (4):849-53
- Goldstein 2001** Goldstein JA. *Clinical relevance of genetic polymorphisms in the human CYP2C subfamily*. Br J Clin Pharmacol. 2001, 52 (4):349-55
- Goldstein und de Morais 1994** Goldstein JA, de Morais SM. *Biochemistry and molecular biology of the human CYP2C subfamily*. Pharmacogenetics. 1994, 4 (6):285-99
- Gotoh 1992** Gotoh O. *Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences*. J Biol Chem. 1992, 5, 267(1):83-90
- Hallberg 2002** Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Melhus H. *The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial*. J Hypertens. 2002, 20 (10):2089-93
- Harrison und Cai 2003** Harrison DG, Cai H. *Endothelial control of vasomotion and nitric oxide production*. Cardiol Clin. 2003, 21 (3):289-302
- Hecker 1994** Hecker M, Bara AT, Bauersachs J, Busse R. *Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals*. J Physiol. 1994,1;481 (2):407-14
- Hichiya 2005** Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, Matsushima E, Uchiyama S, Tokunaga H, Kimura H, Minami N, Katoh M, Sugai K, Goto Y, Tamura T, Yamamoto N, Ohe Y, Kunitoh H, Nokihara H, Yoshida T, Minami H, Saijo N, Ando M, Ozawa S, Saito Y, Sawada J. *Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population*.

Drug Metab Dispos. 2005, 33 (5):630-6

- Higashi 2002** Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. *Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.* JAMA. 2002, 3, 287 (13):1690-8
- Hildebrandt und Roots 1975** Hildebraunt AG, Roots I. *Reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent formation and breakdown of hydrogen peroxide during mixed function oxidation reactions in liver microsomes.* Arch Biochem Biophys. 1975, 171 (2):385-97
- Hillig 2002** Hillig T, Krstrup P, Fleming I, Osada T, Saltin B, Hellsten Y. *Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans.* J Physiol. 2003, 1, 546 (Pt 1):307-14
- Hu und Kim 1993** Hu S, Kim HS. *Activation of K⁺ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid.* Eur J Pharmacol. 1993, 12, 230 (2):215-21
- Huang und Kaley 2004** Huang A, Kaley G. *Gender-specific regulation of cardiovascular function: estrogen as key player.* Microcirculation. 2004, 11 (1):9-38
- Ieiri 2000** Ieiri I, Tainaka H, Morita T, Hadama A, Mamiya K, Hayashibara M, Ninomiya H, Ohmori S, Kitada M, Tashiro N, Higuchi S, Otsubo K. *Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.* Ther Drug Monit. 2000, 22 (3):237-44
- Ignarro 1987** Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. *Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.* Proc Natl Acad Sci U S A. 1987, 84 (24):9265-9
- Ingelman-Sundberg 2002** Ingelman-Sundberg M. *Polymorphism of cytochrome P450 and xenobiotic toxicity.* Toxicology. 2002, 27, 181-182:447-52
- Inoue 1994** Inoue K, Inazawa J, Suzuki Y, Shimada T, Yamazaki H, Guengerich FP, Abe T. *Fluorescence in situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1.* Jpn J Hum Genet. 1994, 39 (3):337-43

- Jessen-Urstad und Johansson 2001** Jensen-Urstad K, Johansson J. *Gender difference in age-related changes in vascular function*. J Intern Med. 2001, 250 (1):29-36
- Karara 1992** Karara A, Wei S, Spady D, Swift L, Capdevila JH, Falck JR. *Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma*. Biochem Biophys Res Commun. 1992, 14, 182 (3):1320-5
- Kawano 1997** Kawano H, Motoyama T, Kugiyama K, Hirashima O, Ohgushi M, Fujii H, Ogawa H, Yasue H. *Gender difference in improvement of endothelium-dependent vasodilation after estrogen supplementation*. J Am Coll Cardiol. 1997, 30 (4):914-9
- Kidd 1999** Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. *Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele*. Pharmacogenetics. 1999, 9 (1):71-80
- Kidd 2001** Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. *Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin*. Pharmacogenetics. 2001, 11 (9):803-8
- Kikuta 1991** Kikuta Y, Sogawa K, Haniu M, Kinosaki M, Kusunose E, Nojima Y, Yamamoto S, Ichihara K, Kusunose M, Fujii-Kuriyama Y. *A novel species of cytochrome P-450 (P-450ib) specific for the small intestine of rabbits. cDNA cloning and its expression in COS cells*. J Biol Chem. 1991, 25, 266 (27):17821-5
- King 2002** King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L, Spiecker M, Liao JK, Mohrenweiser H, Zeldin DC. *Cloning of CYP2J2 gene and identification of functional polymorphisms*. Mol Pharmacol. 2002, 61 (4):840-52
- Kirchheiner 2003** Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmoller J. *Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers*. Clin Pharmacol Ther. 2003, 74 (2):186-94
- Kirchheiner und Brockmüller 2005** Kirchheiner J, Brockmoller J. *Clinical consequences of cytochrome P450 2C9 polymorphisms*. Clin Pharmacol Ther. 2005, 77 (1):1-16
- Klose 1999** Klose TS, Blaisdell JA, Goldstein JA. *Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs*. J Biochem Mol Toxicol. 1999, 13 (6):289-95

- Krötz 2004** Krotz F, Riexinger T, Buerkle MA, Nithipatikom K, Gloe T, Sohn HY, Campbell WB, Pohl U. *Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids*. *Arterioscler Thromb Vasc Biol*. 2004, 24 (3):595-600
- Larsen 2006** Larsen BT, Gutterman DD, Hatoum OA. *Emerging role of epoxyeicosatrienoic acids in coronary vascular function*. *Eur J Clin Invest*. 2006, 36 (5):293-300
- Lee 2002** Lee CR, Goldstein JA, Pieper JA. *Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data*. *Pharmacogenetics*. 2002, 12 (3):251-63
- Lee 2003** Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. *Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals*. *Pharmacotherapy*. 2003, 23 (6):720-5
- Lin 1996** Lin JH, Kobari Y, Zhu Y, Stemerman MB, Pritchard KA Jr.. *Human umbilical vein endothelial cells express P450 2C8 mRNA: cloning of endothelial P450 epoxygenase*. *Endothelium*. 1996, 4:219-229
- Liu 2001** Liu MY, Hattori Y, Fukao M, Sato A, Sakuma I, Kanno M. *Alterations in EDHF-mediated hyperpolarization and relaxation in mesenteric arteries of female rats in long-term deficiency of oestrogen and during oestrus cycle*. *Br J Pharmacol*. 2001, 132 (5):1035-46
- Llorens 2002** Llorens S, Jordan J, Nava E. *The nitric oxide pathway in the cardiovascular system*. *J Physiol Biochem*. 2002, 58 (3):179-88
- Matoba 2000** Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A. *Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice*. *J Clin Invest*. 2000, 106 (12):1521-30
- McGiff und Quilley 1999** McGiff JC, Quilley J. *20-HETE and the kidney: resolution of old problems and new beginnings*. *Am J Physiol*. 1999, 277 (3 Pt 2):R607-23
- McGuire 2001** McGuire JJ, Ding H, Triggle CR. *Endothelium-derived relaxing factors: a focus on endothelium-derived hyperpolarizing factor(s)*. *Can J Physiol Pharmacol*. 2001, 79 (6):443-70
- Miners und Birkett 1998** Miners JO, Birkett DJ. *Cytochrome P4502C9: an enzyme of major importance in human drug metabolism*. *Br J Clin*

Pharmacol. 1998, 45 (6):525-38

- Moncada und Higgs 1991** Moncada S, Higgs EA. *Endogenous nitric oxide: physiology, pathology and clinical relevance*. Eur J Clin Invest. 1991, 21 (4):361-74
- Nelson 1996** Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. *P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature*. Pharmacogenetics. 1996, 6 (1):1-42
- Node 1999** Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. *Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids*. Science. 1999, 20, 285 (5431):1276-9
- Node 2001** Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC, Liao JK. *Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids*. J Biol Chem. 2001, 11, 276 (19):15983-9
- Oltman 1998** Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC. *Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation*. Circ Res. 1998, 2, 83 (9):932-9
- Omura 1999** Omura T. *Forty years of cytochrome P450*. Biochem Biophys Res Commun. 1999, 266 (3):690-8
- Omura und Sato 1962** Omura T, Sato R. *A new cytochrome in liver microsomes*. J Biol Chem. 1962, 237:1375-6
- Pagliari 2004** Pagliaro P, Penna C, Rastaldo R, Mancardi D, Crisafulli A, Losano G, Gattullo D. *Endothelial cytochrome P450 contributes to the acetylcholine-induced cardiodepression in isolated rat hearts*. Acta Physiol Scand. 2004, 182 (1):11-20
- Palmer 1987** Palmer RM, Ferrige AG, Moncada S. *Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor*. Nature. 1987, 11-17, 327 (6122):524-6
- Passauer 2003** Passauer J, Bussemaker E, Lassig G, Pistrosch F, Fauler J, Gross P, Fleming I. *Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole*. Clin Sci (Lond). 2003, 105 (4):513-8

- Puntarulo und Cederbaum 1998** Puntarulo S, Cederbaum AI. *Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes*. Free Radic Biol Med. 1998, 24 (7-8):1324-30
- Quilley und McGiff 2000** Quilley J, McGiff JC. *Is EDHF an epoxyeicosatrienoic acid?* Trends Pharmacol Sci. 2000, 21 (4):121-4
- Raghavan und Dikshit 2004** Raghavan SA, Dikshit M. *Vascular regulation by the L-arginine metabolites, nitric oxide and agmatine*. Pharmacol Res. 2004, 49 (5):397-414
- Rettie 1994** Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. *Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9*. Pharmacogenetics. 1994, 4 (1):39-42
- Rettie 1999** Rettie AE, Haining RL, Bajpai M, Levy RH. *A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin*. Epilepsy Res. 1999, 35 (3):253-5
- Roman 2002** Roman RJ. *P-450 metabolites of arachidonic acid in the control of cardiovascular function*. Physiol Rev. 2002, 82 (1):131-85
- Rostaldo 2001** Rastaldo R, Paolocci N, Chiribiri A, Penna C, Gattullo D, Pagliaro P. *Cytochrome P-450 metabolite of arachidonic acid mediates bradykinin-induced negative inotropic effect*. Am J Physiol Heart Circ Physiol. 2001, 280 (6):H2823-32
- Sacerdoti 1989** Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Levere RD, Schwartzman ML. *Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats*. Science. 1989, 20, 243 (4889):388-90
- Sakuma 2002** Sakuma I, Liu MY, Sato A, Hayashi T, Iguchi A, Kitabatake A, Hattori Y. *Endothelium-dependent hyperpolarization and relaxation in mesenteric arteries of middle-aged rats: influence of oestrogen*. Br J Pharmacol. 2002, 135 (1):48-54
- Sadow und Hill 2000** Sadow SL, Hill CE. *Incidence of myoendothelial gap junctions in the proximal and distal mesenteric arteries of the rat is suggestive of a role in endothelium-derived hyperpolarizing factor-mediated responses*. Circ Res. 2000, 18, 86(3):341-6
- Schwartzman 1985** Schwartzman M, Carroll MA, Ibrahim NG, Ferreri NR, Songu-Mize E, McGiff JC. *Renal arachidonic acid metabolism. The third pathway*. Hypertension. 1985, 7 (3 Pt 2):1136-44

- Shimokawa 1996** Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M, Takeshita A. *The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation.* J Cardiovasc Pharmacol. 1996, 28 (5):703-11
- Shimokawa und Matoba 2004** Shimokawa H, Matoba T. *Hydrogen peroxide as an endothelium-derived hyperpolarizing factor.* Pharmacol Res. 2004, 49 (6):543-9
- Spiecker und Liao 2005** Spiecker M, Liao JK. *Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids.* Arch Biochem Biophys. 2005, 15, 433 (2):413-20
- Spieker und Luscher 2005** Spieker LE, Luscher TF. *Protection of endothelial function.* Handb Exp Pharmacol. 2005, (170):619-44
- Sullivan-Klose 1996** Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. *The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.* Pharmacogenetics. 1996, 6 (4):341-9
- Sun 2002** Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK. *Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids.* Circ Res. 2002, 17, 90 (9):1020-7
- Tagawa 1994** Tagawa T, Imaizumi T, Endo T. *Role of nitric oxide in reaktive hyperemia in human forearm vessels.* Circulation 1994, 90: 2285-90
- Takanashi 1998** Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H. *Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.* Pharmacogenetics. 1998, 8 (5):365-73
- Taylor und Weston 1988** Taylor SG, Weston AH. *Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium.* Trends Pharmacol Sci. 1988, 9 (8):272-4
- Thurman 1972** Thurman RG, Ley HG, Scholz R. *Hepatic microsomal ethanol oxidation. Hydrogen peroxide formation and the role of catalase.* Eur J Biochem. 1972, 25 (3):420-30

- Tousoulis 2005** Tousoulis D, Antoniadis C, Stefanadis C. *Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques*. Heart. 2005, 91 (4):553-8
- Van Rollis 1996** VanRollins M, Kaduce TL, Fang X, Knapp HR, Spector AA. *Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells*. J Biol Chem. 1996, 14, 271 (24):14001-9
- Vanhoutte und Shimokawa 1989** Vanhoutte PM, Shimokawa H. *Endothelium-derived relaxing factor and coronary vasospasm*. Circulation. 1989, 80 (1):1-9
- Verstuyft 2001** Verstuyft C, Morin S, Robert A, Lorient MA, Beaune P, Jaillon P, Becquemont L. *Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers*. Pharmacogenetics. 2001, 11 (8):735-7
- Weintraub 1997** Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. *Potential of endothelium-dependent relaxation by epoxyeicosatrienoic acids*. Circ Res. 1997, 81 (2):258-67
- Wilkinson and Webb 2001** Wilkinson IB, Webb DJ. *Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications*. Br J Clin Pharmacol. 2001, 52 (6):631-46
- Williams 2006** Williams IL, Chowienczyk PJ, Wheatcroft SB, Patel A, Sherwood R, Momin A, Shah AM, Kearney MT. *Effect of fat distribution on endothelial-dependent and endothelial-independent vasodilatation in healthy humans*. Diabetes Obes Metab. 2006, 8 (3):296-301
- Wu 1996** Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. *Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart*. J Biol Chem. 1996, 16, 271 (7):3460-8
- Wu 1997** Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, Zeldin DC. *Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes*. J Biol Chem. 1997 May 9, 272 (19):12551-9
- Xie 2002** Xie HG, Prasad HC, Kim RB, Stein CM. *CYP2C9 allelic variants: ethnic distribution and functional significance*. Adv Drug Deliv Rev. 2002, 18;54 (10):1257-70
- Yamazaki 1998** Yamazaki H, Inoue K, Shimada T. *Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome*

P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica. 1998, 28 (2):103-15

Yasar 2002

Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A. *Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.* Biochem Biophys Res Commun. 2002, 22, 299 (1):25-8

Yasar 2003

Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, Rane A. *Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.* Pharmacogenetics. 2003, 13 (12):715-20

Zeldin 1995

Zeldin DC, Wei S, Falck JR, Hammock BD, Snapper JR, Capdevila JH. *Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis.* Arch Biochem Biophys. 1995, 10, 316 (1):443-51

Zhao 2003

Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. *Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension.* Hypertension. 2003, 41 (3 Pt 2):709-14